Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - Concert Pharmaceuticals, Inc. (Private) |
|
|
“The vision behind Concert is to take a different tack at drug discovery that would enable the creation of new chemical entities (NCEs), first-and best-in-class new medicines, in a way that substantially reduces the risks associated with current drug development approaches and increases the likelihood of their successful commercial development.” - Roger Tung, Ph.D. (Interview published February 19, 2009) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | SERVICES | HOME PAGE |
|
Jan. 4, 2010 07:30 ET
Concert Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11
LEXINGTON, Mass.--(BUSINESS
WIRE)--
Concert
Pharmaceuticals, Inc. announced today that it
will be presenting at the 28th Annual J.P.
Morgan Healthcare Conference, being held at the Westin
St. Francis Hotel in San Francisco, California. Roger
Tung, Ph.D., President and
Chief
Executive Officer of Concert, will present an
overview of the Company
on Monday, January 11, 2010 at 9:00 a.m. (PT).
About Concert Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. In 2009, Concert entered into a potential $1 billion strategic alliance with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com. Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert Pharmaceuticals, Inc. Contacts
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284 Senior Director, Corporate Communications and Investor Relations
|
|
